Enveric Biosciences Inc vs Vanguard S&P 500 ETF — how do they compare? Enveric Biosciences Inc trades at $1.35 (market cap $5.32M), while Vanguard S&P 500 ETF trades at $692.71. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | VOO | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $17.40 | $698.29 |
52-Week Low | $1.28 | $571.45 |
Enterprise Value | $408.82K | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VOO trades at $691.59, up 0.07% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the S&P 500, offering diversified exposure to large-cap U.S. stocks. Recent news highlights its role in retirement portfolios and long-term wealth building, with a dividend of $1.96 scheduled for June 30, 2026.
Outlook remains positive given broad market exposure and low-cost structure, though risks include S&P 500 volatility and macroeconomic shifts. Analyst sentiment is generally favorable, emphasizing its suitability for passive investors seeking steady growth amid potential market corrections.
Trailing returns across standard periods
Latest headlines on both assets
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →